Search ETON
Eton Pharmaceuticals, Inc.
NasdaqGM · CIK 1710340
Last close55.36
Daily change+3.38 (6.50%)
10 Years gain+785.76%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ETON · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
79.5Momentum
100.0Acceleration
100.0Confidence
70.0Annual Revenue7
Quarterly Revenue29
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality21.5 / 25
Capital Efficiency20.0 / 20
Balance Sheet9.1 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 20.26 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 21.9482%.
Low interest coverage · HIGHInterest coverage is 2.7133x.
Key Metrics
Revenue Growth TTM131.25%OK
Revenue CAGR 3Y55.53%OK
Gross Margin58.05%OK
Operating Margin11.98%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC28.38%OK
Incremental Operating Margin 3Y32.87%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y21.95%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $79.95M | $42.74M | -$844,000.00 | $10.52M | $10.19M | 53.46% | -1.06% | 12.75% | -1.9% | n/a |
| 2025 FY Dec 31, 2024 | $39.01M | $23.41M | -$2.60M | $969,000.00 | $943,000.00 | 60.01% | -6.66% | 2.42% | -12.29% | n/a |
| 2025 FY Dec 31, 2023 | $31.64M | $21.06M | -$1.19M | $6.82M | $6.82M | 66.56% | -3.77% | 21.54% | n/a | n/a |
| 2024 FY Dec 31, 2022 | $21.25M | $14.32M | -$8.26M | $4.82M | $4.78M | 67.38% | -38.87% | 22.51% | -122.62% | n/a |
| 2023 FY Dec 31, 2021 | $21.83M | $19.01M | -$1.50M | -$4.72M | -$4.73M | 87.05% | -6.85% | -21.67% | -20.81% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $103.24M | sum latest 4 fiscal quarters Revenue | OK | 0001437749-26-027684, 0001437749-25-033619 |
| Revenue Growth TTM | 131.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001437749-26-027684, 0001437749-25-033619 |
| Revenue CAGR 3Y | 55.53% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-009059 |
| Revenue CAGR 5Y | 359.57% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001437749-26-009059 |
| Gross Profit CAGR 3Y | 43.99% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001437749-26-009059 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001437749-26-027684, 0001437749-25-033619 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 58.05% | Gross Profit / Revenue | OK | 0001437749-26-027684, 0001437749-25-033619 |
| Operating Margin | 11.98% | Operating Income / Revenue | OK | 0001437749-26-027684, 0001437749-25-033619 |
| ROIC | 28.38% | NOPAT / Average Invested Capital | OK | 0001437749-26-027684, 0001437749-25-033619 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001437749-26-027684 |
| Interest Coverage | 2.71x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 1.52x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.96x | (Cash + Short-term Investments) / Total Debt | OK | 0001437749-26-027684 |